Evidence map›Paper›PMID 39330919›Full record

ArticleJournal of extracellular vesicles2024

Beyond basic characterization and omics: Immunomodulatory roles of platelet-derived extracellular vesicles unveiled by functional testing.

Mari Palviainen, Johanna Puutio, Rikke Halse Østergaard, Johannes A Eble, Katariina Maaninka, Umar Butt, Joseph Ndika, Otto K Kari, Masood Kamali-Moghaddam, Kasper Kjaer-Sorensen and 8 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Mari PalviainenEV Group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, and CURED, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-7105-3543
Johanna PuutioEV Group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, and CURED, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-5519-7053
Rikke Halse ØstergaardDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-6341-3871
Johannes A EbleInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany.
Katariina MaaninkaEV Group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, and CURED, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-1211-3267
Umar ButtEV Group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, and CURED, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0696-9520
Joseph NdikaDrug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-2326-5821
Otto K KariDrug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-3133-0670
Masood Kamali-MoghaddamDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Kasper Kjaer-SorensenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Claus OxvigDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Ana M AransayGenome Analysis Platform, Center for Cooperative Research in Biosciences, Basque Research and Technology Alliance (BRTA), Mendaro, Spain.ORCID 0000-0002-8271-612X
Juan M Falcon-PerezCentro de Investigación Biomédica en Red de Enfermedades Hepáticas Y Digestivas (CIBERehd), Madrid, Spain.
Antonio FedericoFinnish Hub for Development and Validation of Integrated Approaches (FHAIVE); Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Dario GrecoFinnish Hub for Development and Validation of Integrated Approaches (FHAIVE); Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Saara LaitinenResearch and Development, Finnish Red Cross Blood Service (FRCBS), Helsinki, Finland.
Yuya HayashiDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Pia R-M SiljanderEV Group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, and CURED, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

Funding

Business Finland 1842/31/2019Deutsche Forschungsgemeinschaft SFB1009 project A09Finnish Red Cross Blood Service Research FundMagnus Ehrnrooth FoundationMedicinska Understödsföreningen Liv och Hälsa rfNovo Nordisk Foundation NNF21OC0067359Orion Research FoundationResearch Council of Finland 287089Research Council of Finland 315227Research Council of Finland 330486Research Council of Finland 332761Swedish Research Council 2020-02258Tampere Institute for Advanced Study
6 · The paper itself

Abstract

Renowned for their role in haemostasis and thrombosis, platelets are also increasingly recognized for their contribution in innate immunity, immunothrombosis and inflammatory diseases. Platelets express a wide range of receptors, which allows them to reach a variety of activation endpoints and grants them immunomodulatory functions. Activated platelets release extracellular vesicles (PEVs), whose formation and molecular cargo has been shown to depend on receptor-mediated activation and environmental cues. This study compared the immunomodulatory profiles of PEVs generated via activation of platelets by different receptors, glycoprotein VI, C-type lectin-like receptor 2 and combining all thrombin-collagen receptors. Functional assays in vivo in zebrafish and in vitro in human macrophages highlighted distinct homing and secretory responses triggered by the PEVs. In contrast, omics analyses of protein and miRNA cargo combined with physicochemical particle characterization found only subtle differences between the activated PEV types, which were insufficient to predict their different immunomodulatory functions. In contrast, constitutively released PEVs, formed in the absence of an exogenous activator, displayed a distinct immunomodulatory profile from the receptor-induced PEVs. Our findings underscore that PEVs are tunable through receptor-mediated activation. To truly comprehend their role(s) in mediating platelet functions among immune cells, conducting functional assays is imperative.

Indexed as

Blood PlateletsExtracellular VesiclesPlatelet ActivationZebrafishAnimalsHumansImmunomodulationMacrophagesMicroRNAsPlatelet Membrane GlycoproteinsMicroRNAsPlatelet Membrane Glycoproteinsextracellular vesiclesfunctional assaysimmunomodulatoryinflammationinnate immunitymacrophagesmiRNAplateletsprotein corona

Identifiers

PMID39330919
PMCPMC11428872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.